The effect of PDE5 inhibitors on smooth muscles has been employed in a wide variety of pharmaceutical applications, such as treatment of erectile dysfunction (ED), benign prostatic hypertrophy (BPH) and pulmonary arterial hypertension (PAH) [29]. The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.